A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Inclusion Criteria:

• Have a diagnosis of chronic migraine as defined by the IHS ICHD-3 guidelines (1.3according to ICHD-3 [2018]), that is, a headache occurring on 15 or more days permonth for at least the last 3 months, which has the features of migraine headache onat least 8 days per month.

Exclusion Criteria:

• Participants who are taking, or are expected to take, therapeutic antibodies duringthe course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.).Prior use of therapeutic antibodies is allowed if that use was more than 12 monthsprior to baseline, except for antibodies to CGRP or its receptor, which are notallowed at any time prior to study entry.

• Known hypersensitivity monoclonal antibodies or other therapeutic proteins, or togalcanezumab or its excipients.

• Current use or prior exposure to galcanezumab, another CGRP antibody, or CGRPreceptor antibody, including those who have previously completed or withdrawn fromthis study or any other study investigating a CGRP antibody. Participant must alsonot have prior oral CGRP antagonist use within 30 days prior to baseline.

• History of IHS ICHD-3 diagnosis of new daily persistent headache, cluster headacheor migraine subtypes including hemiplegic (sporadic or familial) migraine andmigraine with brainstem aura (previously basilar-type migraine).

• History of significant head or neck injury within 6 months prior to screening; ortraumatic head injury at any time that is associated with significant change in thequality or frequency of their headaches, including new onset of migraine followingtraumatic head injury.

• Participants with a known history of intracranial tumors or developmentalmalformations including Chiari malformations.